Oncotelic Therapeutics, Inc. (OTLC)
OTLC is quoted over the counter, not listed on an exchange. Oncotelic Therapeutics, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | OTLC, quoted over the counter |
| SEC CIK | 0000908259 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Aguora Hills, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the date of this filing." | 10-Q 2026-08-13 |
| Cash and burn | $186K cash; operating cash flow -$381K a quarter. | Report 2026-06-30 |
| Shares outstanding | 457,512,796 (2026-08-13); 434,929,966 a year earlier; 398,159,128 three years earlier. | Cover page 2026-08-13 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Rose, Snyder & Jacobs LLP, Encino, California, United States | PCAOB Form AP 2026-04-15 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-03-31 |
| Insider trades, 12 months | Bought $38K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $250K | $388K | -$92K | $186K | $1.9M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$2.2M | -$342K | $64K | $1.8M | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | $250.4M | -$783K | $89K | $1.7M | Needs four quarters | 10-Q 2026-08-13 |
| Q3 2025 2025-09-30 | Not filed | -$1.0M | -$307K | $409K | No debt tags | Needs four quarters | 10-Q 2025-11-17 |
| Q2 2025 2025-06-30 | Not filed | $278K | -$126K | $88K | $2.7M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$299K | -$167K | $79K | $2.6M | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$601K | -$104K | $86K | $2.4M | Needs four quarters | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | Not filed | -$3.3M | -$143K | $149K | $2.4M | Needs four quarters | 10-Q 2025-11-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-12-23 |
| Latest annual report | 10-K | 2026-04-15 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-10-26 |
| Latest proxy | DEF 14A | 2020-06-25 |
Source: SEC EDGAR submissions feed, 1,008 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier